Salvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to market
Eindhoven, the Netherlands, May 27, 2025: Salvia BioElectronics, a clinical-stage medical device company pioneering neuromodulation therapy for people with chronic migraine, today announced the successful completion of a $60 million (€53 million) Series B financing round. The round was led by Innovation Industries, a European deeptech venture capital firm, with participation from Invest-NL and EIC Fund. Existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM and Thuja Capital also joined the round. The funds enable Salvia to complete clinical development and prepare for the commercial launch of MySalvia Therapy, which is currently evaluated in the RECLAIM study, a multi-center, double-blind, sham-controlled study for people with chronic migraine. The funds also allow Salvia to focus on obtaining FDA market authorization in the US and regulatory approvals in Europe and Australia.
